Syed Naqvi

Assistant Professor

UAMS

Also affiliated: The University of Texas MD Anderson Cancer Center (2018–2019); King Edward Medical University (2024); University of Kentucky (2022); Dow University of Health Sciences (2025); Imperial College London Diabetes Centre (2020); Winthrop Rockefeller Foundation (2024); Mayo Hospital (2024); Government College University, Lahore (2024); Jeonbuk National University (2025); Western Kentucky University (2022)

Faculty Researcher

COM | Internal Med Hem-Onc

8 h-index 27 pubs 289 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Syed Naqvi's research focuses on the application of machine learning and data analysis to various scientific domains, including environmental monitoring and healthcare. His work has explored the identification and risk assessment of pollutants using machine learning techniques, as seen in studies on microplastics and organic pollutants in honey. In the medical field, Naqvi has investigated factors affecting patient outcomes, such as weight loss and dysgeusia in multiple myeloma patients treated with talquetamab. He also contributed to a systematic review and meta-analysis on the use of self-expanding metal stents for malignant colon obstruction. Naqvi's research network includes collaborators such as Sabah Syed, Hira Imad Cheema, Elena Ambrogini, and Trilok Shrivastava, all at the University of Arkansas for Medical Sciences, with whom he has co-authored multiple publications. His scholarly output is reflected in an h-index of 8 and over 27 publications.

Metrics

h-index: 8
Publications: 27
Citations: 289

Selected Publications

The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Research Square DOI OpenAlex
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal DOI OpenAlex
Real-world effectiveness and safety of enfortumab vedotin plus pembrolizumab versus gemcitabine-platinum chemotherapy in first-line treatment of advanced urothelial carcinoma: A propensity-matched analysis from the TriNetX global network. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-world comparative outcomes of abiraterone vs enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC): A propensity-matched analysis from the TriNetX Global Health Research Network. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network. (2025)

Blood DOI OpenAlex
Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network. (2025)

Blood DOI OpenAlex
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025)

Blood DOI OpenAlex
MM-1225: Comparison of Short-Term Outcomes and Safety Profile Between Daratumumab-Based Quadruplet Versus Triplet Induction Regimens for Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: Meta-Analysis of Randomized Controlled Trials (2025)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
MM-1211: A 22-Year Snapshot of Demographic and Regional Disparities in Multiple Myeloma Patients with Renal Failure (1999–2020) (2025)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025)

Experimental Hematology and Oncology 3 citations DOI OpenAlex
Discontinuation of levothyroxine therapy in patients with subclinical hypothyroidism: a pilot randomized clinical trial (2025)

Endocrine 7 citations DOI OpenAlex
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)

Frontiers in Hematology 1 citation DOI OpenAlex
MM-084 Advancing Multiple Myeloma Treatment: A Systematic Review and Meta-Analysis of Cereblon E3 Ligase Modulatory Drugs (CELMoDs) Impact on Patient Outcomes (2024)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex